Key Highlights
- Per-share loss was USD 1.74; the market had expected a USD 0.82 loss.
- Collaboration Revenue of USD 2.22 million compared with a USD 2.58 million estimate.
- Net loss widened to USD 28.12 million from USD 17.88 million.
- Cash and short-term investments together reached USD 901.0 million on September 30.
ADARx Pharmaceuticals (NASDAQ:ADRX) lost USD 1.74 per share in the third quarter of 2026. The market had expected a loss of USD 0.82, and the same quarter of 2025 had produced a loss of USD 1.85. Collaboration revenue was USD 2.22 million, against an expected USD 2.58 million.
The net loss was USD 28.12 million, against USD 17.88 million, and the loss from operations was USD 32.18 million, against USD 23.01 million. Weighted-average shares for the quarter numbered 16,127,078.
A Cash Pile Built Around the IPO
At September 30, 2026, cash, cash equivalents and short-term investments came to USD 901.0 million. Cash and cash equivalents accounted for USD 570.61 million, up from USD 66.52 million at the prior Balance Sheet date, and short-term investments for USD 330.40 million, down from USD 413.48 million.
The company believes these holdings are enough to fund operations, counting the net proceeds it received in October 2026 after underwriters took up their full option on additional IPO shares. The filing puts those net proceeds at about USD 62.3 million, after roughly USD 4.6 million of Underwriting discounts and commissions.
Where the Money Went
Research and development spending was USD 26.71 million, against USD 19.42 million, and general and administrative spending was USD 7.68 million, against USD 5.15 million. Total operating expenses were USD 34.39 million, against USD 24.56 million. Interest income was USD 3.48 million.
Over the nine months ended September 30, 2026, the net loss was USD 76.54 million, against USD 51.53 million, and the loss per share was USD 6.46, against USD 5.35. Total operating expenses were USD 94.23 million, against USD 63.78 million, and the loss from operations was USD 89.12 million, against USD 62.02 million. Research and Development took USD 75.03 million, against USD 49.38 million, and general and administrative USD 19.20 million, against USD 14.40 million.
The Agazisiran Programs
The filing says a Phase 1 trial examined the safety, tolerability, pharmacokinetics and pharmacodynamics of agazisiran. Three Phase 2 trials are now testing its efficacy and safety for patients whose diseases are driven by complement, among them the renal conditions IgA nephropathy, complement 3 glomerulopathy and immune complex membranoproliferative glomerulonephritis. Onvuzosiran and ADX-626 are also named as programs, alongside two extrahepatic-targeted programs, ADX-077 and ADX-199.
The balance sheet shows total liabilities of USD 354.66 million, an accumulated Deficit of USD 297.24 million and total stockholders' Equity of USD 574.40 million. Over the nine months, investing activities provided USD 78.61 million of cash and financing activities provided USD 502.10 million.
The Quarter in Brief
ADARx closed the third quarter of 2026 with a net loss of USD 28.12 million and a loss of USD 1.74 per share. Cash, cash equivalents and short-term investments totaled USD 901.0 million, and the company's lead program, agazisiran, is in Phase 2 testing.






Please wait processing your request...